Ondine Biomedical Inc. Appoints Cameron Lawrence as Chief Operating & Financial Officer
VANCOUVER, British Columbia, Oct. 1, 2018
VANCOUVER, British Columbia, Oct. 1, 2018 /PRNewswire-PRWeb/ -- Ondine Biomedical Inc. today announced the appointment of Cameron Lawrence as the company's Chief Operating & Financial Officer. A seasoned executive in the high-tech and biopharmaceutical industries, Mr. Lawrence brings extensive experience in acquisitions, financings, and operational improvement to the Ondine leadership team.
Mr. Lawrence previously served in positions of increasing responsibility, included Chief Financial Officer and later General Manager and Chief Executive Officer, of PNI Digital Media, a publicly traded technology Company prior to its acquisition by Staples Inc. in 2013.
Prior to joining PNI, Mr. Lawrence served as Principal Financial Officer of OncoGenex Pharmaceuticals, Inc., a publicly traded biopharmaceutical company based in Bothell, WA. and Vancouver, Canada.
"Having Cameron join the Ondine team significantly adds to our executive team's capabilities. He brings extensive operational and financial expertise to Ondine as we continue our trajectory as a growing biomedical company," said Carolyn Cross, Ondine's Chairman and CEO.
"I am delighted to be joining Ondine during this exciting time in the company's growth. Ondine is uniquely positioned to address unmet patient needs in both the infection control and chronic sinusitis markets. I look forward to supporting the team as we progress our ongoing clinical programs and expand our commercial initiatives," said Mr. Lawrence.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. Ondine's platform technology is called photodisinfection, a patented, light-activated technology that provides rapid antimicrobial efficacy without encouraging antibiotic resistance.
Ondine currently has numerous applications of its photodisinfection technology at various stages of development, including SinuwaveTM, a product to treat chronic rhinosinusitis (CRS). Ondine's lead product is the MRSAid™ nasal decolonization system which is used to eradicate pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), from the nose in hospitalized patients. Additional products in the healthcare-associated infection and CRS markets are currently under development.
Contact Ondine Biomedical Inc.
Angelika Vance, Director – Corporate Development
SOURCE Ondine Biomedical Inc.